alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
NUMBER 13-10-00338-CV

COURT OF APPEALS

THIRTEENTH DISTRICT OF TEXAS

CORPUS CHRISTI - EDINBURG

____________________________________________________________

MARIE PECORE AND DANIEL PECORE, Appellants,

v.

RADIOLOGY ASSOCIATES, LLP, Appellee.

____________________________________________________________

On Appeal from the 105th District Court 

of Nueces County, Texas.

____________________________________________________________

MEMORANDUM OPINION

Before Chief Justice Valdez and Justices Rodriguez and Garza

Memorandum Opinion Per Curiam

Appellants, Marie Pecore and Daniel Pecore, filed an appeal from a judgment 

entered by the 105th District Court of Nueces County, Texas, in cause number 09-167-D. 

Appellants have filed an “Appellants’ Notice of Nonsuit as to all Defendants.” Appellants

request that this Court dismiss the appeal without prejudice.
2

The Court, having considered the documents on file and appellants’ motion to 

dismiss the appeal, is of the opinion that the motion should be granted. See TEX. R. APP.

P. 42.1(a). Appellants’ motion to dismiss is granted, and the appeal is hereby 

DISMISSED WITHOUT PREJUDICE. In accordance with the agreement of the parties, 

costs are taxed against the party incurring same. See TEX. R. APP. P. 42.1(d) ("Absent 

agreement of the parties, the court will tax costs against the appellant."). Having 

dismissed the appeal at appellants’ request, no motion for rehearing will be entertained, 

and our mandate will issue forthwith.

PER CURIAM

Delivered and filed the

14th day of July, 2011.
CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350



AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002





In connection with the quarterly report of New Mexico Software, Inc. (the "Company") on Form 10-QSB for the quarter ended September 30, 2007, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), the undersigned principal executive officer and the principal financial officer of the Company, hereby certify pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:



(1)

the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and



(2)

the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.



Date:  November 13, 2007









/s/ Richard Govatski

Richard Govatski, President

(Principal Executive Officer)









/s/ Teresa Dickey

Teresa Dickey, Treasurer

(Principal Financial Officer)
<PAGE>   1


                                  EXHIBIT 10.5

                        AMENDMENT TO EMPLOYMENT AGREEMENT

       THIS AMENDMENT TO EMPLOYMENT AGREEMENT dated as of the 31st day of
December, 1998 by and between GENELINK, INC., a Pennsylvania corporation (the
"Company"), and JOHN R. DEPHILLIPO ("Executive").

                                   BACKGROUND

       The Company and Executive are parties to an Employment Agreement dated as
of February 24, 1998 (the "Original Employment Agreement"), pursuant to which
Executive is employed as president and chief executive officer of the Company.

       The parties hereto desire to amend the Employment Agreement as further
set forth below.

       NOW, THEREFORE, in consideration of the foregoing and the mutual
covenants contained herein, the parties agree as follows:

       1.     Amendment to Paragraph 3(d). Paragraph 3(d) of the Original
Employment Agreement is hereby amended to read in its entirety as follows:

       "(d) Repayment of Loans. Executive may pay any loans or advances made to
       him by the Company using cash, Company Shares, options to acquire Company
       Shares, or any combination, by December 31, 2003, unless extended by the
       Company."

       2.     Full Force and Effect. Except as expressly amended hereby, the
Original Employment Agreement shall remain valid, binding and in full force and
effect.


                                       1
<PAGE>   2


       IN WITNESS WHEREOF, the parties have executed this Amendment as of the
date first above written.


                                                 /s/ John DePhillipo
                                                 -------------------------------
                                                 JOHN DEPHILLIPO


                                                 GENELINK, INC.


                                                 By: /s/ John R. DePhillipo
                                                     ---------------------------








                                       2
UNITED STATES OF AMERICA

Before the

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Administrative Proceedings Rulings

Release No. 6832 / October 18, 2021

Administrative Proceeding

File No. 3-20627

In the Matter of the Registration 

Statement of

Life Science Holdings, Inc., 

 6445 12th Ave. South, Minneapolis, MN 

 55423

Order Designating 

Presiding Judge

The Securities and Exchange Commission has ordered that the hearing in 

this matter commence at 10:00 a.m. on Tuesday, November 2, 2021, via remote 

means and/or at Commission Headquarters, Hearing Room 2, 100 F Street, 

N.E., Washington, D.C. 20549. 

IT IS ORDERED that Administrative Law Judge Carol Fox Foelak 

preside at the hearing in these proceedings and perform other and related 

duties in accordance with the Commission’s Rules of Practice. 

Service of all orders and rulings on parties is made by the Commission’s 

Office of the Secretary, or other duly authorized Commission officer, pursuant 

to Commission Rule of Practice 141, 17 C.F.R. § 201.141. All issuances by 

administrative law judges are posted on the Commission’s website at 

http://www.sec.gov/alj.

For the Commission, by its Acting Chief Administrative Law Judge, 

pursuant to delegated authority.

 

/s/ James E. Grimes 

Acting Chief Administrative Law Judge
§ 571.21 Procedures. ( a ) An inmate is eligible for a gratuity as determined by the availability of personal and community resources. Greater consideration may be given to an inmate without funds or community resources.
( b ) A federal prisoner boarded in a non-federal facility is eligible for a release gratuity. The director of the non-federal facility housing federal inmates or the community corrections manager shall determine the amount of release gratuity in accordance with the purpose and scope of this regulation for federal inmates housed in non-federal facilities.
( c ) An inmate who is without personal funds may receive a gratuity when transferred to a community corrections center. The amount shall enable the inmate to care for needs in transit and allow for the purchase of necessary personal items upon arrival.
( d ) Staff shall provide the inmate released to a detainer with information on how to apply for a gratuity if released prior to expiration of the federal sentence.
( e ) Staff will ensure that each alien released to immigration authorities for the purpose of release or transfer to a community corrections center has $10 cash. This provision does not apply to aliens being released for the purpose of deportation, exclusion, or removal, or to aliens detained or serving 60 days or less in contract facilities.
[56 FR 23480, May 21, 1991, as amended at 68 FR 34300, June 9, 2003]
#### §§ 39.152-39.159 [Reserved]
#### § 540.102 Monitoring of inmate telephone calls.

The Warden shall establish procedures that enable monitoring of telephone conversations on any telephone located within the institution, said monitoring to be done to preserve the security and orderly management of the institution and to protect the public. The Warden must provide notice to the inmate of the potential for monitoring. Staff may not monitor an inmate's properly placed call to an attorney. The Warden shall notify an inmate of the proper procedures to have an unmonitored telephone conversation with an attorney.

[48 FR 24622, June 1, 1983. Redesignated at 59 FR 15824, Apr. 4, 1994]
II 

116TH CONGRESS 

1ST SESSION S. 91 

To amend title 38, United States Code, to authorize per diem payments 

under comprehensive service programs for homeless veterans to furnish 

care to dependents of homeless veterans, and for other purposes. 

IN THE SENATE OF THE UNITED STATES 

JANUARY 10, 2019 

Mr. GARDNER (for himself and Mrs. MURRAY) introduced the following bill; 

which was read twice and referred to the Committee on Veterans’ Affairs 

A BILL 

To amend title 38, United States Code, to authorize per 

diem payments under comprehensive service programs 

for homeless veterans to furnish care to dependents of 

homeless veterans, and for other purposes. 

1 Be it enacted by the Senate and House of Representa2 tives of the United States of America in Congress assembled, 

3 SECTION 1. SHORT TITLE. 

4 This Act may be cited as the ‘‘Creating a Reliable 

5 Environment for Veterans’ Dependents Act of 2019’’. 


kjohnson on DSK79L0C42 with BILLS
2 

•S 91 IS

1 SEC. 2. AUTHORIZATION OF PER DIEM PAYMENTS FOR 

2 FURNISHING CARE TO DEPENDENTS OF CER3 TAIN HOMELESS VETERANS. 

4 Section 2012(a) of title 38, United States Code, is 

5 amended by adding at the end the following new para6 graph: 

7 ‘‘(4) Services for which a recipient of a grant under 

8 section 2011 of this title (or an entity described in para9 graph (1)) may receive per diem payments under this sub10 section may include furnishing care for a dependent of a 

11 homeless veteran who is under the care of such homeless 

12 veteran while such homeless veteran receives services from 

13 the grant recipient (or entity).’’. 

Æ 


kjohnson on DSK79L0C42 with BILLS
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Small Business Administration

Pursuant to the authority granted to the United States Small Business Administration by the Wind-Up Order of the United States District Court of the Eastern District of New York, dated July 15, 2009, the United States Small Business Administration hereby revokes the license of Sterling/Carl Marks Capital, Inc., a New York corporation, to function as a small business investment company under the Small Business Investment Company License No. 02020517 issued to Sterling/Carl Marks Capital, Inc., on October 3, 1988 and said license is hereby declared null and void as of July 15, 2009.

Dated: March 4, 2011.

Sean J. Greene, 

Associate Administrator for Investment, United States Small Business Administration.

[FR Doc. 2011-6475 Filed 3-18-11; 8:45 am]

BILLING CODE 8025-01-P
UNITED STATES


SECURITIES AND EXCHANGE COMMISSION


Washington, D.C. 20549





FORM 8-K





CURRENT REPORT


Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934





Date of Report (Date of earliest event reported) May 10, 2011





Progenics Pharmaceuticals, Inc.


(Exact name of registrant as specified in its charter)





Delaware

000-23143

13-3379479(State or other jurisdiction

of incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)777 Old Saw Mill River Road, Tarrytown, New York

10591(Address of principal executive offices)

(Zip Code)Registrant's telephone number, including area code (914) 789-2800





Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):








oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)





oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))




oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))











Item 2.02.                      Results of Operations and Financial Condition.




Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its operational results for the quarter ended March 31, 2011.  A copy of its press release is included in this Report as Exhibit 99.1.






The information furnished pursuant to this Item 2.02 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section, unless we specifically incorporate it by reference in a document filed under the Exchange Act or the Securities Act of 1933. We undertake no duty or obligation to publicly update or revise the information so furnished.




Item 9.01.                      Financial Statements and Exhibits.





(d) Exhibits





Exhibit No.                      Description





99.1                      Press Release dated May 10, 2010.








SIGNATURES








Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.








PROGENICS PHARMACEUTICALS, INC.


By:/s/ ROBERT A. MCKINNEY


Robert A. McKinney


Chief Financial Officer, Senior Vice President,


Finance & Operations and Treasurer











Date: May 10, 2011
Michigan Supreme Court

Lansing, Michigan

Bridget M. McCormack, Chief Justice

David F. Viviano,

Chief Justice Pro Tem

Stephen J. Markman

Brian K. Zahra

Richard H. Bernstein

Elizabeth T. Clement

Megan K. Cavanagh,

Justices

I, Larry S. Royster, Clerk of the Michigan Supreme Court, certify that the

foregoing is a true and complete copy of the order entered at the direction of the Court.

 April 22, 2020

t0415

Order 

Clerk

April 22, 2020

159748

PEOPLE OF THE STATE OF MICHIGAN,

Plaintiff-Appellee,

v SC: 159748

COA: 333535

Macomb CC: 2014-003080-FC

MARK ANTHONY VARNER,

Defendant-Appellant.

_________________________________________/

On order of the Court, the application for leave to appeal the April 16, 2019 

judgment of the Court of Appeals is considered, and it is DENIED, because we are not 

persuaded that the questions presented should be reviewed by this Court.
#### § 505.6 Procedures for payment.

Fees imposed pursuant to this part are due and payable after notice of the Unit Team actions. When the inmate participates in the inmate financial responsibility program (see 28 CFR part 545, subpart B), fees are to be included under the category “other federal government obligations” and are to be paid before other financial obligations included in that same category. Fees may be subject to interest charges.
Don’t feel well? 

Tell An Adult If You Feel Sick

If you feel sick, tell your mom or dad or caregiver 

before you come to camp. If you get sick at camp, 

tell your counselor or an adult right away.

cough

chills

CS 317450-A June 24, 2020 9:09 AM

cdc.gov/coronavirus

Other symptoms 

include: 

fever, runny nose, diarrhea, feeling nauseous

or vomiting, feeling tired, headache, 

and poor appetite

muscle pain

shortness of breath

or 

difficulty

breathing

sore throat

loss of smell or taste
### §1159. Federal agency consultations with and technical assistance to Secretary of Commerce or Commission; reimbursement for assistance

The head of any Federal agency is authorized to consult with and provide technical assistance to the Secretary or the Commission whenever such assistance is needed and reasonably can be furnished in carrying out the provisions of this subchapter. Any Federal agency furnishing assistance hereunder may expend its own funds for such purposes, with or without reimbursement.

(Pub. L. 89–702, title I, §109, Nov. 2, 1966, 80 Stat. 1093; Pub. L. 98–129, §2, Oct. 14, 1983, 97 Stat. 838.)

#### **Editorial Notes**

#### Amendments

1983—Pub. L. 98–129 amended section generally, substituting provisions authorizing Federal agency consultation with and technical assistance to the Secretary or the Commission, which were previously contained in section 1158 of this title, for provisions defining terms. See section 1151 of this title.
EXHIBIT 32.2  Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley act of 2002  In connection with the Quarterly Report of Teliphone Corp. (the “Company”) on Form 10–Q for the period ended March 31, 2013, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Benoit Laliberte, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes–Oxley Act of 2002, to the best of his knowledge, that:  1.       The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and  2.       The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.  /s/Benoit LaliberteBenoit Laliberte
Principal Financial and Accounting Officer  Dated: May 30, 2013
§ 385.1005 Replies (Rule 1005). ( a ) *By the Secretary.* Within 20 days of service of the petition for review, the Secretary will file with the Commission and serve on the petitioners and the other participants in prior proceedings on the contested order, a reply to the petition for review stating fully his or her position supported by arguments to the petition for review.
( b ) *By other participants.* A person who participated in prior proceedings on the contested order may be a participant in the proceedings pursuant to this subpart and may make filings and submittals as determined by the presiding officer.
( c ) *By interveners.* A person who was denied the opportunity to participate in prior proceedings on the contested order or who is aggrieved or adversely affected by the contested order may move to intervene in accordance with Rule 214 (intervention). In order that the motion be granted, the movant must show, as appropriate, that denial of participation in prior proceedings was wrongful or why he or she is aggrieved or adversely affected by the contested order. If the presiding officer grants the motion, the person submitting the motion to intervene may make filings and submittals as determined by the presiding officer.
( d ) A participant may request interim relief in a proceeding pursuant to this subpart.
( e ) The presiding officer may require such other filings by the participants as he or she deems necessary in the conduct of the proceedings.
[Order 225, 47 FR 19022, May 3, 1982, as amended by Order 422, 50 FR 21600, May 28, 1985]
§ 34.100 Purpose and applicability. ( a ) This subpart of the regulation implements section 262(d)(2) of the Juvenile Justice and Delinquency Prevention Act of 1974, as amended. This provision requires that projects funded as new or continuation programs selected for categorical assistance awards under part C—National Programs shall be reviewed before selection and thereafter as appropriate through a formal peer review process. Such process must utilize experts (other than officials and employees of the Department of Justice) in fields related to the technical and/or subject matter of the proposed program.
( b ) This subpart of the regulation applies to all applications for grants, cooperative agreements, and other assistance awards selected by the Administrator, OJJDP, for funding under part C—National Programs that are being considered for competitive and noncompetitive (including continuation) awards to begin new project periods, except as provided in the exceptions to applicability set forth below.
### §230g. Authorization of appropriations; general management plan; submission to Congressional committees

(a) There is authorized to be appropriated, to carry out the provisions of this part, not to exceed $50,000,000 from the Land and Water Conservation Fund for acquisition of lands, waters, and interests therein and such sums as necessary for the development of essential facilities.

(b) Within three years from November 10, 1978, the Secretary, after consultation with the Commission, shall submit to the Committee on Interior and Insular Affairs of the House of Representatives, and the Committee on Energy and Natural Resources of the Senate a general management plan for the park indicating—

(1) transportation alternatives for public access to the park;

(2) the number of visitors and types of public use within the park which can be accommodated in accordance with the protection of its resources;

(3) the location and estimated cost of facilities deemed necessary to accommodate such visitors and uses; and

(4) a statement setting forth the actions which have been and should be taken to assure appropriate protection, interpretation, and management of the areas known as Big Oak Island and Couba Island.

(Pub. L. 95–625, title IX, §908, Nov. 10, 1978, 92 Stat. 3537.)

#### **Statutory Notes and Related Subsidiaries**

#### Change of Name

Committee on Interior and Insular Affairs of the House of Representatives changed to Committee on Natural Resources of the House of Representatives on Jan. 5, 1993, by House Resolution No. 5, One Hundred Third Congress.

#### "Secretary" Defined

Secretary means the Secretary of the Interior, see section 2 of Pub. L. 95–625, set out as a note under section 45f of this title.
#### § 512.18 Termination or suspension.

The Director, Bureau of Prisons, may suspend or terminate a research project if it is believed that the project violates research policy or that its continuation may prove detrimental to the inmate population, the staff, or the orderly operation of the institution.
EXHIBIT 99.1
 
     
 
 TARRYTOWN, NY, July 16, 2013 –
 
  
  Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in late-stage clinical development. Progenics' first-in-class PSMA targeted technology platform includes an antibody drug conjugate therapeutic and a small molecule targeted imaging agent, both in Phase 2 clinical trials. is Azedra TM , . Progenics' first commercial product, Relistor ® (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. Ono Pharmaceutical Co. is developing Relistor in Japan. For additional information, please visit www.progenics.com .
### §3146. Transportation alternatives portion of study

In studying oil and gas alternative transportation systems, the Secretary shall consult with the Secretary of Transportation and shall consider—

(1) the extent to which environmentally and economically feasible alternative routes could be established;

(2) the prospective oil and gas production potential of this area of Alaska for each alternative transportation route; and

(3) the environmental and economic costs and other values associated with such alternative routes.

(Pub. L. 96–487, title X, §1006, Dec. 2, 1980, 94 Stat. 2453.)